Arbele has developed proprietary technology platforms to generate new Immunotherapeutics possessing multiple anti-tumor mechanisms for greater efficacy.
Cutting-edge proprietary technologies to address solid tumors:
AI-CAR/NK cell therapeutic platform
TriAx multipspecific antibody platform
pAC01 single-vector system for trispecific biomanufacturing in CHO cells
CA-17 diagnostics (for tissue and liquid biopsies) – companion and POC tests
Arbele is harnessing this successful approach to develop a potential first-in-class biologic, ARB-202, to treat refractory colon, gastric and pancreatic cancers. ARB202 is a humanized antibody that recognizes the specific tumor antigen CDH17 and the T-cell receptor CD3. It is built on an IgG-scFv framework and has a two-two tetra valency.
Arbele is developing the next generation of CAR technology, where multiple components are added to the patient's T cells in addition to the CAR. Arbele is even exploring the use of a different patient cell type, natural killer or NK cells, which could be even more powerful and safer than T cells and may not require the use of the patient's own cells, i.e. “off-the-shelf” products.